Curis (NASDAQ:CRIS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Curis (NASDAQ:CRIS) in a research note released on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Curis in a report on Tuesday, December 10th.

Curis Stock Performance

CRIS opened at $2.32 on Friday. Curis has a twelve month low of $2.30 and a twelve month high of $17.49. The firm has a market cap of $19.64 million, a price-to-earnings ratio of -0.30 and a beta of 3.49. The firm’s 50-day simple moving average is $3.04 and its 200-day simple moving average is $3.89.

Institutional Trading of Curis

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC acquired a new position in Curis in the 4th quarter valued at $35,000. Millennium Management LLC grew its stake in shares of Curis by 92.6% in the fourth quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 12,287 shares in the last quarter. Focused Wealth Management Inc increased its position in Curis by 9.5% during the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after acquiring an additional 5,138 shares during the period. Geode Capital Management LLC raised its stake in Curis by 27.3% in the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 17,820 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in Curis in the 4th quarter valued at about $607,000. Institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.